未治疗肌层浸润性膀胱癌的自然史
基于瑞典斯德哥尔摩1995至1996年新诊断膀胱癌数据库,126例临床局限肌层浸润性膀胱癌中64例(51%)未接受根治性治疗。未治疗组6个月时38%已发生转移、41%死于膀胱癌,5年总生存率5%对治疗组48%,5年癌症特异性死亡累积发生率86%对48%,未治疗组转移进展风险更高(HR 2.40)。
要点
- 未治疗肌层浸润性膀胱癌患者6个月时38%发生转移、41%死于膀胱癌。
- 未治疗组5年总生存率5%(95%CI 1,12%)vs 治疗组48%(95%CI 36,60%)。
- 未治疗组5年癌症特异性死亡累积发生率86%(95%CI 75,94%)vs 治疗组48%(95%CI 36,60%)。
核心结论
- 未治疗的肌层浸润性膀胱癌患者近期癌症特异性死亡风险非常高。
- 这些发现可能有助于权衡整合治愈性意图治疗的获益与风险,尤其在老年肌层浸润性膀胱癌患者中。
研究设计与样本
- 利用瑞典斯德哥尔摩1995至1996年新诊断膀胱癌数据库,共538例膀胱癌患者中126例为临床局限肌层浸润性膀胱癌。
- 将患者分为接受根治性膀胱切除术或放疗组与未接受任何形式治疗组,存活者中位随访14.4年。
- 采用多变量Cox回归或竞争风险回归预测转移、总生存和癌症特异性死亡,并校正诊断年龄、性别、肿瘤分期、临床N分期和治疗。
主要发现
- 64例(51%)未接受任何确定性局部治疗;未治疗组诊断时中位年龄79(63-83)岁 vs 治疗组69(63-74)岁(P < 0.001)。
- 随访期间共109例死亡;未治疗组诊断后6个月时38%已发生转移性疾病、41%发生癌症特异性死亡。
- 未治疗组与治疗组5年总生存率分别为5%(95%CI 1,12%)vs 48%(95%CI 36,60%)。
- 未治疗组5年癌症特异性死亡累积发生率为86%(95%CI 75,94%)vs 治疗组48%(95%CI 36,60%)。
- 未治疗组转移进展风险更高(HR 2.40,95%CI 1.28,4.51;P = 0.006)、全因死亡风险更高(HR 2.63,95%CI 1.65,4.19;P < 0.001)、癌症特异性死亡风险更高(亚分布HR 2.02,95%CI 1.24,3.30;P = 0.004)。
临床怎么用
- 原文结论指出这些发现可能有助于权衡整合治愈性意图治疗的获益与风险,尤其在老年肌层浸润性膀胱癌患者中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the natural history of untreated muscle-invasive bladder cancer (MIBC) and compare the oncological outcomes of treated and untreated patients. PATIENTS AND METHODS: We utilised a database encompassing all patients with newly diagnosed bladder cancer in Stockholm, Sweden between 1995 and 1996. The median follow-up for survivors was 14.4 years. Overall, 538 patients were diagnosed with bladder cancer of whom 126 had clinically localised MIBC. Patients were divided into two groups: those who received radical cystectomy or radiation therapy, and those who did not receive any form of treatment. Multivariable Cox or competing-risks regressions were adopted to predict metastasis, overall survival (OS), and cancer-specific mortality (CSM), when appropriate. Analyses were adjusted for age at diagnosis, sex, tumour stage, clinical N stage, and treatment. RESULTS: In all, 64 (51%) patients did not receive any definitive local treatment. In the untreated group, the median (interquartile range) age at diagnosis was 79 (63-83) vs 69 (63-74) years in the treated group (P < 0.001). Overall, 109 patients died during follow-up. At 6 months after diagnosis, 38% of the untreated patients had developed metastatic disease and 41% had CSM. The 5-year OS rate for untreated and treated patients was 5% (95% confidence interval [CI] 1, 12%) vs 48% (95% CI 36, 60%), respectively. Patients not receiving any treatment had a 5-year cumulative incidence of CSM of 86% (95% CI 75, 94%) vs 48% (95% CI 36, 60%) for treated patients. Untreated patients had a higher risk of progression to metastatic disease (hazard ratio [HR] 2.40, 95% CI 1.28, 4.51; P = 0.006), death from any cause (HR 2.63, 95% CI 1.65, 4.19; P < 0.001) and CSM (subdistribution HR 2.02, 95% CI 1.24, 3.30; P = 0.004). CONCLUSIONS: Untreated patients with MIBC are at very high risk of near-term CSM. These findings may help balance the risks vs benefits of integrating curative intent therapy particularly in older patients with MIBC.
引用
- Martini A, Sfakianos JP, Renström-Koskela L, et al. The natural history of untreated muscle-invasive bladder cancer. BJU Int. 2019. PMID: 31310696. doi:10.1111/bju.14872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。